Catena Biosciences
- Biotech or pharma, therapeutic R&D
- Biotech or pharma, animal health
CatenaBio is a novel Biotech spun out of the laboratories of Jennifer Dounda and Matt Francis at UC Berkeley. Catena’s selective enzymatic conjugation approach is significantly superior to other technologies and enables therapeutic structures not possible before; it’s poised to disrupt the ADC space by enabling multiple payloads on a single antibody along with flexibility of several conjugation sites per antibody. CatenaBio is developing a novel pipeline of early Dual-payload ADCs using this platform, with the lead asset in NHP studies after successful multi-grams scale up through CDMO. Early Tox data are expected in the coming weeks. Catena’s technology allows for the attachment of payloads beyond the small molecules used in today’s ADCs. Catena has demonstrated conjugation of a multiple compounds from toxins, isotope chelators, nucleic acids, peptides, enzymes, cytokines, nano bodies, and even whole cells.
Address
BerkeleyCalifornia
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}